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Percutaneous aortic valve replacement (TAVR) 
is a cutting-edge technology and one of the bre-
akthroughs in cardiovascular medicine in the last 
decade and, for these reasons, some considerations 
must be taken even at risk that some of them might 
soon become outdated as a result of the exponen-
tially growing medical evidence and experience 
about this technique [1].
The number of patients who could benefit 
from a TAVR is highly variable in different regions 
of the world, and many of them do not even have 
good estimations [2]. However, according to an 
European survey, approximately 30% of those pa-
tients with severe aortic stenosis requiring aortic 
valve replacement (AVR) do not currently receive 
the proper surgery for different reasons but high 
surgical risk appears as one of the most common 
cause for surgery contraindication [3]; moreover, 
considering that global population is aging, I have 
the expectation that the percentage and total 
number of patients who can benefit from TAVR 
will grow dramatically in few years.
These estimations can also vary depending 
on the threshold to indicate TAVR or AVR by open 
surgery (AVRbyOS) by each Heart Team. This will 
be influenced by recommendations in guidelines, 
local experience, and the economic situation of 
the region, which will affect cost/effectiveness 
relationship. For example, in Latin America, in 
those patients where TAVR may be an alternative 
with similar medical outcomes but more expensive, 
AVRbyOS will remain as the standard of care.
However, in some regions the target will not 
be this group of patients but rather those requiring 
AVR having a high risk or contraindication for 
AVRbyOS. In my opinion, octogenarians without 
other comorbidities will be the first intermediate 
risk group that will be electively treated by TAVR 
in a short time.
Patient selection must be performed by 
a multidisciplinary team with different training and 
expertise covering all the aspects that are necessa-
ry for taking care of this highly complex patient 
population, working in an adequate environment 
(Heart Team) [4, 5]. However, it is likely that 
these structures will simplify to make them more 
efficient, but access to consultations and specific 
care when required must be kept.
This also leads me to a belief that the practi-
ce will continue on an upward trend in the use of 
femoral approach, reserving all the other vascular 
access for particular situations. Nevertheless, 
vascular complication rate, which is an important 
predictor of mortality, should be maintained low and 
minimized if possible [6–8]. Technological deve-
lopments leading to devices and delivery systems 
miniaturization with new altogether with better 
vascular closure devices will facilitate this trend 
and will make the so call “minimalist approach” 
to increase. This approach consists of using local 
anesthesia [9–11], percutaneous access [12, 13] 
and transthoracic ultrasound for the implantation.
The published outcomes with the two most 
studied devices worldwide are very encouraging 
despite the initial series have used first-generation 
devices and included the learning curve of the ope-
rators [14–17]. Although there are not randomized 
clinical trials comparing balloon expandable systems 
vs. self-expanding; there are large series of patients 
reported which did not show significant differences 
between them [18], except with valve-in-valve for the 
treatment of degenerated bioprosthesis, where there 
has been found a lower residual gradient using the 
CoreValve (Medtronic’s self-expanding system) [19].
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On the other hand, most of the series have 
shown an increased incidence of vascular compli-
cations using the Edwards system, mainly with the 
larger first generation device; and a higher need for 
permanent pacemaker implantation (PPM) when 
the CoreValve system is used [18]. The possibility 
of partial repositioning is a potential advantage of 
CoreValve, and possibility of recapturing and com-
plete repositioning is a feature shared by other new 
devices that have been introduced to the market 
recently.
Postprocedural residual paravalvular leaks 
leaving a moderate-severe aortic regurgitation 
(AR) are associated with worse clinical outcomes; 
mainly with a higher 1-year mortality rate [20].
Proper planning, including patient selection 
using multiple images, taking into account the 
elliptical shape of the aortic annulus are extremely 
important not only for the patient but also for de-
vice selection [21]. Along with more experienced 
operators [22] and improvement in the design of 
the device, it will definitively reduce paravalvular 
leaks and other complications.
At the beginning of the study, the efforts to 
correct a moderate AR were not frequent, as many 
operators believed that it would be very well tole-
rated and will have no impact on late clinical evo-
lution, but this concept has changed dramatically. 
However, if we do not get an optimal outcome after 
trying to correct all potential causes of leaks and 
AR, we have to be very cautious when thinking 
about the possibility of an emergency AVRbyOS 
in this situation.
Conduction disturbances occur frequently 
after TAVR, being left branch blocking the most 
common. Although, in a series it was associated to 
high long-term mortality rate, this has been refuted 
by later series including more patients. Nor has 
an increase in late mortality due to the need for 
PPM [23], which is more frequent after TAVR than 
AVRbyOS. Although it has been a downward trend, 
it has been higher with CoreValve in comparison 
with Edwards-Sapien valves. A high implantation 
of the prosthesis (< 6 mm from aortic annulus) 
and the absence or a conservative predilatation 
decrease the need for PPM, while the new onset 
left bundle branch block increases it [24]. PPM is 
not a determining factor for long-term outcomes, 
but ideally this requirement should be less.
Periprocedural stroke rate was a significant 
concern after the publications of the initial series 
reporting a stroke rate between 5% and 10%, 
however this incidence has declined over time 
(3.8–6.7% in more recent publications; 2% in our 
series). Although the stroke rate is lower than 
before, many efforts are done trying to improve 
these outcomes even more, but it does not seem 
an easy goal to be achieved. In the PARTNER 
trial, periprocedural stroke was more frequent in 
the group of patients receiving TAVR vs. those 
receiving AVRbyOS.
Cerebral embolization, demonstrated by new 
ischemic defects detected by magnetic resonance 
imaging is highly frequent but it has limited clinical 
manifestation [25]. This study has also shown that 
the size of the ischemic defects, when they occur, 
are bigger in the surgical group in comparison with 
TAVR patients [26].
Procedural improvements, such as decreasing 
the number of maneuvers over the aorta and cal-
cified valve, less aggressive or no pre- and post-
-dilatation when they are not mandatory, would 
seem to be the cause of the decline of periproce-
dural stroke rate in later series [27, 28]. The uses 
of aortic flow deflectors and cerebral protection 
devices is an appealing concept which has been 
tested in some preliminary clinical studies which 
have not yet confirmed the effectiveness of these 
devices [29, 30].
Complete and easy valve repositioning is 
a common feature of many new devices which 
increase device manipulations over the aorta and 
calcified valve may also increase the potential of 
cerebral embolization and stroke risk. Nonetheless, 
this has been only a theoretical concern so far.
While TAVR was introduced for percutaneous 
replacement in patients with severe aortic stenosis 
and contraindications or high surgical risk, imme-
diately after, came up the possibility to use it in 
cases of pure or predominant AR and also in cases 
of degenerated surgical bioprosthesis implanted by 
a prior open-heart surgery.
There are some recent series reporting promi-
sing outcomes with the use of CoreValve [31] and 
JenaValve [32] in patients with AR, with a higher 
need of intraprocedural valve-in-valve in the series 
with CoreValve. However, it would be ideal to have 
a randomized clinical trial before it is routinely used 
in daily clinical practice.
A different situation occurs in those patients 
requiring valve-in-valve due to degenerated surgi-
cal bioprostheses, because the information provi-
ded by the multicenter registry [33] can be consi-
dered enough, since the option of re-operation has 
a higher risks for most of these patients. Perhaps 
the only data to be confirmed is the long-term 
durability of the percutaneous graft in this speci-
fic situation where it has not been widely tested. 
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Patients with thrombus or active endocarditis of 
the biological bioprosthesis are not candidates for 
this technique.
Long-term follow-up (beyond 10–15 years) is 
still a major limitation for widespread use of TAVR, 
but it is expected a similar durability to the surgical 
bioprosthesis. Moreover, valve-in-valve procedure 
for endovascular valves is also possible at follow-up 
and can extend valve durability (“secondary durabi-
lity”), while many researches are conducted to find 
new synthetic compound that can replace biological 
tissue that may degenerate over the time.
The presence of concomitant mitral regurgita-
tion increases the risk and uncertainty about late 
evolution and potential need for mitral valve repair 
or replacement after TAVR at follow-up. However, 
some recently published data from a substudy 
of the PARTNER Trial showed that a significant 
number of these patients have a substantial im-
provement in the degree of mitral regurgitation 
and these results have been better for those who 
received TAVR vs. those who only receive AVR-
byOS without any intervention on the mitral valve.
The use of new percutaneous techniques to 
repair, and eventually to replace, mitral valve will 
add a complementary alternative to a higher risk 
population.
Dual adjunctive antiplatelet therapy with aspi-
rin and clopidogrel has been used as the default 
strategy, but it has been a practical application. 
Nonetheless, this concept will be revisited since 
there are no studies to support this strategy over 
others [34]. Moreover, keeping in mind that many 
of these patients are elderly with high risk for 
bleeding, a more effective dual antiplatelet therapy 
strategy may be justified to decrease the stroke 
rate occurring after the procedure but it should 
be counterbalanced with a higher risk of bleeding 
in many of them.
Those patients who have concomitant atrial 
fibrillation, which is a predictor of stroke at 1-year 
follow-up, and at high risk of bleeding, may benefit 
from left atrial appendage closure instead of recei-
ving long-term oral anticoagulation [35].
Coronary revascularization prior to TAVR in 
those patients with severe coronary artery disease 
is a widely used approach for this comorbid situ-
ation, however, there is no solid evidence to justify 
this strategy in patients without previous angina 
or demonstrated ischemia [36]. We can consider it 
only an expert consensus, which may extrapolate 
some concept from cardiovascular surgery and the 
intention to simplify the percutaneous transluminal 
coronary angioplasty, which is technically more 
complex after TAVR. To perform both procedures 
in the same setting appears to be restricted to few 
cases, due to the frailty of many of them and the 
high risk of contrast-induced nephropathy.
We can conclude that although several issu-
es still need to, and could be improved, TAVR is 
consolidating in daily practice as an excellent al-
ternative to AVR by open-heart surgery. A larger 
clinical evidence provided by randomized clinical 
studies with long-term follow-up will conclude that 
TAVR is the first choice for high surgical risk pa-
tients and a good alternative for many others with 
intermediate risk who are still under discussion. 
We all agree on that we are witnessing a paradigm 
shift in the treatment of aortic stenosis with this 
new minimally invasive and highly effective trans-
catheter procedure that has come to stay.
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